Cellsource Co., Ltd. (4880)
JPX JPX Primary Summary
Cellsource Co., Ltd. (4880) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cellsource Co., Ltd. ever had a stock split?
Cellsource Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Masayuki Yamakawa M.D. CEO | JPX Exchange | JP3423580004 ISIN |
| Japan Country | 148 Employees | - Last Dividend | 28 Oct 2021 Last Split | - IPO Date |
Overview
CellSource Co., Ltd. is a company based in Tokyo, Japan, that operates within the regenerative medicine sector. Established in 2015, the company specializes in providing advanced healthcare solutions, focusing on stem cell technology. Its operations are primarily aimed at harnessing the potential of regenerative medicine to offer innovative therapies and products. CellSource's services cater to patients seeking treatment for various conditions, as well as medical facilities engaged in offering regenerative therapies.
Products and Services
- Stem Cell and Platelet-Rich Plasma Processing Services
- Support Services for Medical Facilities
- Signalift Anti-Aging Products
- Manufacturing of Processed Cells
CellSource Co., Ltd. offers specialized processing services that include the extraction of adipose-derived stem cells from a patient's fat tissues and the preparation of platelet-rich plasma from the blood. These services are essential for regenerative medicine procedures, aiding in the treatment and recovery of patients through the promotion of tissue repair and regeneration.
The company extends its expertise by providing support services to medical institutions that offer regenerative medicine therapies. This encompasses a range of assistance, from the implementation of CellSource's technologies to the adoption of best practices in patient care and therapy administration. Through these support services, CellSource ensures that medical facilities are well-equipped to deliver high-quality regenerative treatments.
In addition to its regenerative medicine services, CellSource is involved in the development and sale of the Signalift series of anti-aging products. The series features a serum among its offerings, formulated to leverage the science behind regenerative medicine for cosmetic purposes. These products are designed to meet the growing demand for non-invasive anti-aging solutions, by harnessing the restorative properties of stem cells and other regenerative factors.
Another key area of operation for CellSource is the manufacturing of processed cells. This function supports both the internal needs of the company's service offerings and the wider regenerative medicine industry. By producing high-quality processed cells, CellSource contributes to the advancement of cell-based therapies and the overall field of regenerative medicine.
